Blar i forfatter "Andersen, Jan Terje"

Viser treff 1-5 av 5

    • Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity 

      Søraas, Arne Vasli; Grødeland, Gunnveig; Granerud, Beathe Kiland; Ueland, Thor; Lind, Andreas; Fevang, Børre; Murphy, Sarah Louise Mikalsen; Huse, Camilla; Nygaard, Anders Benteson; Steffensen, Anne Katrine; Al-Baldawi, Huda; Holberg-Petersen, Mona; Andresen, Lise Lima; Ågnes, Camilla; Ranheim, Trine; Schanke, Ylva; Istre, Mette Stausland; Dahl, John Arne; Chopra, Adity; Dudman, Susanne; Kaarbø, Mari; Andersen, Jan Terje; Vaage, Eline Benno; Tran, Trung The; Vaage, John Torgils; Michelsen, Annika Elisabet; Müller, Fredrik; Aukrust, Pål; Halvorsen, Bente Evy; Dahl, Tuva Børresdatter; Holter, Jan Cato; Lund-Johansen, Fridtjof (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-09-08)
      Background: Results showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron have been interpreted as indicating the need for a third vaccine dose for protection. However, there is little information about early immune responses to Omicron infection in double vaccinated individuals.<p> <p>Methods: We measured inflammatory mediators, antibodies to the ...

    • Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn 

      Hallstensen, Randi; Bergseth, Grete; Foss, Stian; Jæger, Steinar; Gedde-Dahl, Thobias; Holt, jan; Christiansen, Dorte; Lau, Corinna; Brekke, Ole Lars; Armstrong, Elina; Stefanovic, Vedran; Andersen, Jan Terje; Sandlie, Inger; Mollnes, Tom Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-11-13)
      Eculizumab is a humanized IgG2/4 chimeric anti-complement C5 antibody used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome. The aim of this study was to evaluate whether or not the complement activity in newborns from pregnant women who receive eculizumab is impaired. A novel eculizumab-C5 complex (E-C5) specific assay was developed and ...

    • NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies. 

      Lau, Corinna; McAdam, MB; Bergseth, G; Grevys, Algirdas; Bruun, JA; Ludviksen, Judith K; Fure, Hilde; Espevik, Terje; Moen, A; Andersen, Jan Terje; Mollnes, Tom Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-11-27)
      The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab (Soliris®), which is used clinically to block complement factor C5, as well as anti-human CD14 (r18D11) and anti-porcine CD14 (rMIL2) produced in our laboratory. So far, no proper IgG2/4 control antibody has been available for controlled ...

    • Prevention of Fetal/Neonatal Alloimmune Thrombocytopenia in Mice: Biochemical and Cell Biological Characterization of Isoforms of a Human Monoclonal Antibody 

      Mørtberg, Trude Victoria; Zhi, Huiying; Vidarsson, Gestur; Foss, Stian; Lissenberg-Thunnissen, Suzanne; Wuhrer, Manfred; Michaelsen, Terje Einar; Skogen, Bjørn; Stuge, Tor Brynjar; Andersen, Jan Terje; Newman, Peter J.; Ahlen, Maria Therese (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-01-01)
      Maternal alloantibodies toward paternally inherited Ags on fetal platelets can cause thrombocytopenia and bleeding complications in the fetus or neonate, referred to as fetal and neonatal alloimmune thrombocytopenia (FNAIT). This is most commonly caused by Abs against the human platelet Ag (HPA)-1a in Caucasians, and a prophylactic regimen to reduce the risk for alloimmunization to women at risk ...

    • Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients 

      Holter, Jan Cato; Pischke, Soeren; de Boer, Eline; Lind, Andreas; Jenum, Synne; Holten, Aleksander Rygh; Tonby, Kristian; Barratt-Due, Andreas; Sokolova, Marina; Schjalm, Camilla; Chaban, Viktoriia; Kolderup, Anette; Tran, Trung; Tollefsrud Gjølberg, Torleif; Skeie, Linda Gail; Hesstvedt, Liv; Ormåsen, Vidar; Fevang, Børre; Austad, Cathrine; Muller, Karl Erik; Fladeby, Cathrine; Holberg-Petersen, Mona; Halvorsen, Bente; Müller, Fredrik; Aukrust, Pål; Dudman, Susanne Gjeruldsen; Ueland, Thor; Andersen, Jan Terje; Lund-Johansen, Fridtjof; Heggelund, Lars; Dyrhol-Riise, Anne Ma; Mollnes, Tom Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-09-17)
      The new SARS-CoV-2 pandemic leads to COVID-19 with respiratory failure, substantial morbidity, and significant mortality. Overactivation of the innate immune response is postulated to trigger this detrimental process. The complement system is a key player in innate immunity. Despite a few reports of local complement activation, there is a lack of evidence that the degree of systemic complement ...